Rituximab Infusion ( DrugBank: Rituximab )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	1
222	Primary nephrotic syndrome	1

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,342 /  Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02040116 (ClinicalTrials.gov)	February 2013	14/1/2014	Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases	Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases	Multiple Sclerosis	Drug: Rituximab Infusion	Wake Forest University Health Sciences	NULL	Completed	18 Years	80 Years	All	19	Phase 4	United States

222. Primary nephrotic syndrome

---

Clinical trials : 285 /  Drugs : 285 - (DrugBank : 108) / Drug target genes : 62 - Drug target pathways : 191

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00977977 (ClinicalTrials.gov)	December 2, 2010	15/9/2009	Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy	Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy	Nephrotic Syndrome;Proteinuria;Autoimmune Disease;Glomerular Disease;Membranous Glomerulonephritis	Drug: Rituximab Infusion;Drug: Oral Cyclosporine	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	NULL	Recruiting	18 Years	N/A	All	30	Phase 2	United States